Compare Caesars Entertainment Inc (CZR) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Caesars Entertainment Inc vs Smith & Nephew plc — how do they compare? Caesars Entertainment Inc trades at $29.49 (market cap $6.02B), while Smith & Nephew plc trades at $27.21 (market cap $11.10B). The key difference: Smith & Nephew plc is the larger of the two by market cap, and Smith & Nephew plc pays a 2.95% dividend while Caesars Entertainment Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Caesars Entertainment Inc for 31 Days and Smith & Nephew plc for 121 Days on average.
| CZR | SNN | |
|---|---|---|
Market Cap | $6.02B | $11.10B |
Volume | 6,412,151 | 1,051,703 |
Sector | Consumer Cyclical | Health |
52-Week High | $30.41 | $37.17 |
52-Week Low | $18.14 | $26.42 |
Typical Hold Time | 31 Days | 121 Days |
Enterprise Value | $29.91B | $14.13B |
Dividend Yield | — | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Caesars Entertainment (CZR) trades at $29.54, showing minimal daily movement with a 0.15% gain. The stock faces bearish technical signals and has missed earnings expectations for three consecutive quarters, with negative profitability metrics including -3.99% net income margin. The pending $31 per share acquisition by Fertitta Entertainment provides a potential floor, while recent news highlights shareholder investigations into the deal's fairness. Cash flow trends show improvement with net cash flow narrowing from -$689M in 2022 to -$32M in 2025.
CZR presents a mixed outlook with acquisition upside limited to 5% from current levels, offset by fundamental challenges including consistent earnings misses and negative margins. Key risks include merger uncertainty and high debt load, while analyst sentiment remains cautious with 68% hold ratings. The stock offers speculative appeal for merger arbitrage but lacks organic growth catalysts.
SNN trades at $27.10, near its 52-week low, with a bearish technical signal. The company reported solid fundamentals with revenue growth to $6.16B in 2025 and a net income margin of 10.08%. Recent product launches, like the EVOS PELVIC System, aim to strengthen its medical technology portfolio. Cash flow from operations remains strong at $1.29B, though net cash flow was negative $64M in 2025.
The outlook is mixed: strong profitability and innovation support long-term value, but near-term headwinds include analyst downgrades and competitive pressures. Risks involve execution challenges and market sentiment. The stock presents a cautious opportunity for value investors, balancing solid fundamentals against current bearish trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Caesars Entertainment Inc
Caesars Entertainment includes around 50 domestic gaming properties across Las Vegas (50% of 2021 EBITDAR before corporate and digital expenses) and regional (63%) markets. Additionally, the company hosts managed properties and digital assets, the later of which produced material EBITDA losses in 2021. Caesars' U.S. presence roughly doubled with the 2020 acquisition by Eldorado, which built its first casino in Reno, Nevada, in 1973 and expanded its presence through prior acquisitions to over 20 properties before merging with legacy Caesars. Caesars' brands include Caesars, Harrah's, Tropicana, Bally's, Isle, and Flamingo. Also, the company owns the U.S. portion of William Hill (it plans to sell the international operation in 2022), a digital sports betting platform.
Read more on CZR →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
